The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors
Open accessAbstract
Anticancer therapeutics employing RNA interference mechanism holds promising potentials for sequence-specific silencing of target genes. However targeted delivery of siRNAs to tumor tissues and cells and more importantly, their intracellular release at sites of interest still remains a major challenge that needs to be addressed before this technique could become a clinically viable option. In the current study, we have engineered and screened a series of CD44 targeting hyaluronic acid (HA) based self-assembling nanosystems for targeted siRNA delivery. The HA polymer was functionalized with lipids of varying carbon chain lengths/nitrogen content, as well as polyamines for assessing siRNA encapsulation. From the screens, several HA-derivatives were identified that could stably encapsulate/complex siRNAs and form self-assembled nanosystems, as determined by gel retardation assays and dynamic light scattering. Many HA derivatives could transfect siRNAs into cancer cells overexpressing CD44 receptors. Interestingly, blocking the CD44 receptors on the cells using free excess soluble HA prior to incubation of cy3-labeled-siRNA loaded HA nano-assemblies resulted in >90% inhibition of the receptor mediated uptake, confirming target specificity. In addition, SSB/PLK1 siRNA encapsulated in HA-PEI/PEG nanosystems demonstrated dose dependent and target specific gene knockdown in both sensitive and resistant A549 lung cancer cells overexpressing CD44 receptors. More importantly, these siRNA encapsulated nanosystems demonstrated tumor selective uptake and target specific gene knock down in vivo in solid tumors as well as in metastatic tumors. The HA based nanosystems thus portend to be promising siRNA delivery vectors for systemic targeting of CD44 overexpressing cancers including tumor initiating (stem-) cells and metastatic lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G. T., Kaplan, M. J., Dalerba, P., Weissman, I. L., Clarke, M. F., & Ailles, L. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610117104 · Cited by 2,164
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“MDR develops due to multiple factors that include poor systemic drug delivery efficiency, inefficient drug residence at the tumor site, poor intracellular availability and micro-environmental selection pressures that allow certain cells to survive despite aggressive chemotherapy [2].”
Exploiting the enhanced permeability and retention effect for tumor targeting
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.005 · Cited by 1,846 · cited 1×
“In selection of the ideal candidate tumors obviously the ones with higher levels of CD44 (that promotes receptor mediated internalization) and higher levels of vascularity that facilitate tumor accumulation based on the EPR effect will show pronounced effect [34,41].”
Self-citationExploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,337
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
RNAi therapeutics: Principles, prospects and challenges
Aagaard, L., & Rossi, J. J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.005 · Cited by 895
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Heterogeneity of tumor cells from a single mouse mammary tumor.
Dexter, D. L., Kowalski, H. M., Blazar, B. A., Fligiel, Z., Vogel, R., & Heppner, G. H. (1978) · PubMed · Cited by 579
Mouse xenograft models vs GEM models for human cancer therapeutics
Richmond, A., & Su, Y. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000976 · Cited by 467
Platt, V. M., & Szoka, F. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800024g · Cited by 456
Co-Delivery of siRNA and An Anticancer Drug for Treatment of Multidrug-Resistant Cancer
Saad, M., Garbuzenko, O. B., & Minko, T. (2008) · Nanomedicine · doi:10.2217/17435889.3.6.761 · Cited by 367
Prospects of RNA interference therapy for cancer
Pai, S. I., Lin, Y.-Y., Macaes, B., Meneshian, A., Hung, C.-F., & Wu, T.-C. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302694 · Cited by 352
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Metastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 309
Nanostructured hyaluronic acid-based materials for active delivery to cancer
Ossipov, D. A. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425241003730399 · Cited by 191
Xiong, X.-B., Uludağ, H., & Lavasanifar, A. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2008.09.025 · Cited by 168
Susa, M., Iyer, A. K., Ryu, K., Choy, E., Hornicek, F. J., Mankin, H. J., Milane, L. S., Amiji, M. M., & Duan, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010764 · Cited by 162
Self-citationHyaluronic acid–polyethyleneimine conjugate for target specific intracellular delivery of siRNA
Jiang, G., Park, K., Kim, J., Kim, K. S., Oh, E. J., Kang, H., Han, S., Oh, Y., Park, T. G., & Hahn, S. K. (2008) · Biopolymers · doi:10.1002/bip.20978 · Cited by 156
Extracellular and intracellular barriers in non-viral gene delivery
Ruponen, M. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.004 · Cited by 151
Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors
Rivkin, I., Cohen, K., Koffler, J. Y., Melikhov, D., Peer, D., & Margalit, R. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.05.067 · Cited by 144
Evolution of tumor cell heterogeneity during progressive growth of individual lung metastases.
Poste, G. H., Tzeng, J., Doll, J., GREIG, R. G., Rieman, D. J., & Zeidman, I. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.21.6574 · Cited by 138
A sensitive method for localization of disulfide containing peptides in column effluents
Habeeb, A. F. S. A. (1973) · Analytical Biochemistry · doi:10.1016/0003-2697(73)90169-3 · Cited by 136
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo
Aigner, A. M. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0984-y · Cited by 135
An insight on hyaluronic acid in drug targeting and drug delivery
Yadav, A. K., Mishra, P., & Agrawal, G. P. (2008) · Journal of drug targeting · doi:10.1080/10611860701794296 · Cited by 130
Combinatorial-Designed Multifunctional Polymeric Nanosystems for Tumor-Targeted Therapeutic Delivery
Abeylath, S. C., Ganta, S., Iyer, A. K., & Amiji, M. M. (2011) · Accounts of Chemical Research · doi:10.1021/ar2000106 · Cited by 119
Self-citationKim, T. H., Nah, J. W., Cho, M., Park, T. G., & Cho, C. S. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.434 · Cited by 117
Probing the mechanism of transport and compartmentalisation of polyamines in mammalian cells.
Cullis, P., Green, R. E., Merson-Davies, L., & Travis, N. (1999) · Chemistry and Biology · doi:10.1016/s1074-5521(00)80019-8 · Cited by 91
Non-viral gene delivery using nanoparticles
Ditto, A. J., Shah, P. N., & Yun, Y. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903241796 · Cited by 87
Lee, Y.-H., Andersen, J. B., Song, H., Judge, A. D., Seo, D., Ishikawa, T., Marquardt, J. U., Kitade, M., Durkin, M. E., Raggi, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0749 · Cited by 71
Lee, H., Choi, S. H., & Park, T. G. (2005) · Macromolecules · doi:10.1021/ma051929c · Cited by 67
RNAi nanomedicines: challenges and opportunities within the immune system
Weinstein, S., & Peer, D. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/23/232001 · Cited by 52
Evaluation of the effect of vector architecture on DNA condensation and gene transfer efficiency
Canine, B., Wang, Y., & Hatefi, A. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.012 · Cited by 36
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery
Li, L., Wang, R., Wilcox, D. M., Zhao, X. B., Song, J. C., Li, X., Kohlbrenner, W. M., Fesik, S. W., & Shen, Y. (2011) · Gene Therapy · doi:10.1038/gt.2011.146 · Cited by 34
Cited by
Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine
Sousa de Almeida, M., Susnik, E., Drasler, B., Taladriz-Blanco, P., Petri-Fink, A., & Rothen-Rutishauser, B. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01127d · Cited by 1,079
Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine
Mattheolabakis, G., Milane, L., Singh, A., & Amiji, M. M. (2015) · Journal of Drug Targeting · doi:10.3109/1061186x.2015.1052072 · Cited by 597
Self-citationHyaluronic acid for anticancer drug and nucleic acid delivery
Dosio, F., Arpicco, S., Stella, B., & Fattal, E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.011 · Cited by 596
MicroRNA delivery through nanoparticles
Lee, S. W. L., Paoletti, C., Campisi, M., Osaki, T., Adriani, G., Kamm, R. D., Mattu, C., & Chiono, V. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.007 · Cited by 437
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Self-citation
Metadata
- Authors
- Ganesh, S., Iyer, A. K., Morrissey, D. V., & Amiji, M. M.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 34
- Issue
- 13
- Pages
- 3489-3502
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W1999327728
- Cited by
- 362
- References
- 36
- FWCI
- 14.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.